Alkermes Granted Orphan Drug Designations for Alixorexton in US, Europe
The investigational oral orexin 2 receptor agonist received designations from the FDA for idiopathic hypersomnia and the European Commission for narcolepsy.
Category: Idiopathic Hypersomnia
Idiopathic Hypersomnia
Latest
Idiopathic Hypersomnia
Latest
Survey Reveals Power of Social Connections for Narcolepsy and IH Patients
A global survey reveals that peer connections significantly improve support and adjustment for individuals with narcolepsy and idiopathic hypersomnia.
Idiopathic Hypersomnia
Latest
Pathophysiology of Idiopathic Hypersomnia
Research has revealed potential clues into the pathophysiology of idiopathic hypersomnia.
‘Rare’ Sleep Disorder More Common Than Expected
New research has found that a sleep disorder thought to be rare may be as common as some other neurologic and psychiatric conditions such as epilepsy, bipolar disorder, and schizophrenia.
Read More
Initiative Launches to Drive Better Understanding of Idiopathic Hypersomnia
The Sleep Consortium, in collaboration with sleep-related patient advocacy organizations worldwide, has launched the Illuminate Hypersomnia initiative, an effort to highlight the lived experience of idiopathic hypersomnia.
Read More
Xywav Maintains Upward Trajectory in Narcolepsy and Idiopathic Hypersomnia Treatment
In the third quarter, low-sodium Xywav grew 30% year-over-year, despite additional competition, with continued adoption across both narcolepsy and idiopathic hypersomnia
Read More
KP1077 for IH and Narcolepsy a Priority for Zevra
In its third-quarter business update, Zevra Therapeutics Inc designated KP1077, its investigational drug in development for idiopathic hypersomnia and narcolepsy, as a pivotal focus area.
Read More
Usage Up for Narcolepsy Drug Wakix in Q3, Harmony Biosciences Reports
Harmony Biosciences reported a 37% increase in net revenue in the third quarter, largely attributed to the growth in patient use of its narcolepsy drug Wakix.
Read More
Jazz Highlights Continued Need for Low-Sodium Treatment Option for Narcolepsy and IH
Jazz Pharmaceuticals announced new data highlighting the importance of low-sodium treatment options to help manage cardiovascular risk in patients with narcolepsy and idiopathic hypersomnia.
Read More
Jazz Spotlights Heart Risks Linked to Narcolepsy and Idiopathic Hypersomnia
At World Sleep 2023, Jazz Pharmaceuticals will spotlight the link between sleep disorders and cardiovascular health through 14 abstracts.
Read More
Pitolisant Misses Primary Endpoint in Phase 3 Study for IH
Topline results from the INTUNE study of pitolisant for idiopathic hypersomnia revealed that the primary endpoint for excessive daytime sleepiness did not achieve statistical significance against a placebo in the randomized withdrawal phase.
Read More
IH Drug Candidate Well-Tolerated Across Doses, Interim Data Shows
Interim data from Zevra Therapeutics’ phase 2 clinical trial of KP1077 in patients with idiopathic hypersomnia indicates the drug is well-tolerated at all tested doses and dosing schedules.
Read More
Jazz: Oxybate Enhances Sleep Quality in Narcolepsy Patients Regardless of Dosing Schedule
The review evaluated all high-sodium oxybates, fixed-dose, and twice-nightly administrations in both oxybate-experienced patients and those who had not undergone prior treatment.
Read More
KP1077 Rivals Ritalin in Heart Safety for Idiopathic Hypersomnia
Zevra Therapeutics highlighted the heart safety of serdexmethylphenidate, the main ingredient in KP1077, its potential treatment for idiopathic hypersomnia, during a poster presentation at Psych Congress 2023.
Read More
Harmony Gets FDA Orphan Drug Designation for Pitolisant for Idiopathic Hypersomnia
Harmony Biosciences is currently evaluating the efficacy and safety of pitolisant in adult patients with idiopathic hypersomnia in a phase 3 study, with topline results anticipated in the fourth quarter.
Read More
Initiative Provides Financial Assistance to Idiopathic Hypersomnia Patients
Financial assistance from The Assistance Fund is now available for eligible people living with idiopathic hypersomnia.
Read More
NLS Eyes Fast-Track Designation for Mazindol ER for Narcolepsy
NLS Pharmaceutics issued a letter updating stakeholders on its progress in developing treatments for sleep disorders, which include Mazindol ER for narcolepsy, NLS-4 for idiopathic hypersomnia, and NLS-11 for Kleine-Levin Syndrome.
Read More
Zevra Advances KP1077 for Idiopathic Hypersomnia and Narcolepsy in Q2
Zevra Therapeutics provided second-quarter corporate updates, showcasing progress for KP1077, a drug candidate being investigated for the treatment of idiopathic hypersomnia and narcolepsy.
Read More